Eli Lilly announced a $6.5 billion investment in a new Houston manufacturing facility to boost production of its drug pipeline, including its experimental obesity pill, orforglipron. This is the second of four planned US facilities totaling over $50 billion in investment since 2020. The new plant will create 615 permanent and 4,000 construction jobs and aims to address supply constraints and meet anticipated high demand for orforglipron.

Prepared by Christopher Adams and reviewed by editorial team.